Trial intelligence / Profile preview

Steno 1: Multifactorial Intervention in Type 1 Diabetes

NCT06082063Phase 3Recruiting

Sponsor: Steno Diabetes Center Copenhagen
Start: Jul 2024
Primary completion: Jul 2029
Modality: Peptides, Recombinant Proteins and Enzymes, Small Molecules
Countries: 1

Overview

Phase 3, randomised, open-label trial of semaglutide, sotagliflozin and finerenone in type 1 diabetes mellitus (T1D) (2 arms), sponsored by Steno Diabetes Center Copenhagen. Primary endpoint: Major Adverse Cardiovascular Events + Hospitalization for Heart Failure at 5 years. Started Jul 2024; status: recruiting.

Drugs

semaglutidesotagliflozinfinerenone

Conditions

type 1 diabetes mellitus (T1D)

Beyond the preview

Go deeper on NCT06082063.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT06082063.